KalVista Pharmaceuticals: Funding, Investors & Team (Sep 2026)
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
KalVista Pharmaceuticals has raised $397M across 3 funding rounds on record, the most recent an undisclosed round of $179M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
KalVista Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2024.
KalVista Pharmaceuticals Funding Rounds
KalVista Pharmaceuticals raised $58.0M in an undisclosed round announced in Dec 2022.
1.2 years later, an undisclosed round of $160M was announced in Feb 2024.
9 months later, an undisclosed round of $179M was announced in Nov 2024.
KalVista Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
KalVista Pharmaceuticals Funding Compared to Other Biotechnology Startups
KalVista Pharmaceuticals' latest round of $179M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like KalVista Pharmaceuticals in Biotechnology and Cambridge
Companies Similar to KalVista Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
KalVista Pharmaceuticals Funding FAQs
What does KalVista Pharmaceuticals do?
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
How much funding has KalVista Pharmaceuticals raised?
KalVista Pharmaceuticals has raised $397M across 3 rounds on record. The most recent is an undisclosed round of $179M announced in Nov 2024.
When did KalVista Pharmaceuticals last raise funding?
KalVista Pharmaceuticals' most recent funding round on record is an undisclosed round of $179M, announced in Nov 2024.
Who founded KalVista Pharmaceuticals?
FundedIQ lists Edward P Feener (Founder), Lloyd P Aiello (Founder) at KalVista Pharmaceuticals.
Where is KalVista Pharmaceuticals headquartered?
KalVista Pharmaceuticals is based in Cambridge, Massachusetts, United States.
How many employees does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals is in the 101-250 employee band.
How does KalVista Pharmaceuticals' funding compare to other Biotechnology startups?
KalVista Pharmaceuticals' latest round of $179M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's KalVista Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for KalVista Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.